^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | erfonrilimab (KN046) (PD-L1 inhibitor, CTLA4 inhibitor) + anbenitamab (KN026) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors
Published date:
11/09/2020
Excerpt:
The objective response rate in pts with HER2-positive tumors (n = 14 efficacy evaluable pts) was 9/14 (64.3%, 95% CI 35.1~87.2%) and disease control rate 13/14 (92.9%, 95% CI 66.1~99.8%). 4 out of 5 pts with HER2 mutation or low expression achieved SD including one patient with SD for more than 24 weeks. 4 out of 5 pts with HER2 mutation or low expression achieved SD including one patient with SD for more than 24 weeks.
DOI:
http://dx.doi.org/10.1136/jitc-2020-SITC2020.0810
